Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.64 |
| ▸ | MEN1 | O00255 | 5/20 | 0.64 |
| ▸ | ATM | Q13315 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.56 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | FPR2 | P25090 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31369624 | 0.90 | S1PR1 (0.55) | KMT2AMEN1ATMSMN1; SMN2FFAR1 | |
| SCHEMBL3196104 | 0.89 | MEN1 (0.62) | KMT2AMEN1ATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL9544789 | 0.87 | SMN1; SMN2 (0.61) | KMT2AMEN1ATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL13113227 | 0.87 | SMN1; SMN2 (0.66) | KMT2AMEN1ATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL4459745 | 0.85 | SMN1; SMN2 (0.59) | KMT2AMEN1ATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL6066919 | 0.84 | MEN1 (0.50) | KMT2AMEN1ATMSMN1; SMN2ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL6066933 | 0.84 | KMT2A (0.50) | KMT2AMEN1ATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL9487686 | 0.83 | MEN1 (0.60) | KMT2AMEN1ATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL1807496 | 0.83 | MEN1 (0.61) | KMT2AMEN1ATMALDH1A1KDM4E | |
| SCHEMBL13101471 | 0.83 | KMT2A (0.56) | KMT2AMEN1ATMSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026282-B1 | Peptide antagonists of the human urokinase receptor and method for selecting them | Cancerforskningsfonden AF 1989 (Fonden Til Fremme AF Exsperimentel Cancerforskning) (DK) | 2006-04-11 | — | — | US | claimed |
| WO-2000001802-A2 | PEPTIDE ANTAGONISTS OF THE HUMAN UROKINASE RECEPTOR AND METHOD FOR SELECTING THEM | CANCERFORSKNINGSFONDEN AF 1989 (FONDEN TIL FREMME AF EKSPERIMENTEL CANCERFORSKNING) (DK) | 2000-01-13 | — | — | WO | claimed |
| US-12281180-B2 | Peptoid-peptide macrocycles, pharmaceutical compositions and methods of using the same | NEW YORK UNIVERSITY (US) | 2025-04-22 | — | — | US | disclosed |
| WO-2024040245-A1 | PEPTIDE DERIVATIVES AND RELATED USES AS OREXIN AGONISTS | CENTESSA PHARMACEUTICALS (OREXIA) LIMITED (GB) | 2024-02-22 | — | — | WO | disclosed |
| WO-2024040237-A1 | PEPTIDE DERIVATIVES AND RELATED USES AS OREXIN AGONISTS | CENTESSA PHARMACEUTICALS (OREXIA) LIMITED (GB) | 2024-02-22 | — | — | WO | disclosed |
| WO-2024015797-A1 | PEPTIDE DERIVATIVES AND RELATED USES AS OREXIN AGONISTS | CENTESSA PHARMACEUTICALS (OREXIA) LIMITED (GB) | 2024-01-18 | — | — | WO | disclosed |
| WO-2023017180-A1 | PEPTIDE DERIVATIVES AND RELATED USES AS OREXIN AGONISTS | OREXIA THERAPEUTICS LIMITED (GB) | 2023-02-16 | — | — | WO | disclosed |
| US-20130109581-A1 | POSITIVELY CHARGED SPECIES AS BINDING REAGENTS IN THE SEPARATION OF PROTEIN AGGREGATES FROM MONOMERS | NOVARTIS AG (CH) | 2013-05-02 | — | — | US | disclosed |
| EP-1931695-B1 | Prion-specific peptoid reagents | NOVARTIS AG (CH) | 2013-04-10 | — | — | EP | disclosed |
| EP-2496947-A1 | POSITIVELY CHARGED SPECIES AS BINDING REAGENTS IN THE SEPARATION OF PROTEIN AGGREGATES FROM MONOMERS | Novartis AG (CH) | 2012-09-12 | — | — | EP | disclosed |
| US-20120027677-A1 | Prion-specific peptoid reagents | NOVARTIS AG | 2012-02-02 | — | — | US | disclosed |
| WO-2011057029-A1 | POSITIVELY CHARGED SPECIES AS BINDING REAGENTS IN THE SEPARATION OF PROTEIN AGGREGATES FROM MONOMERS | NOVARTIS AG (CH) | 2011-05-12 | — | — | WO | disclosed |
| EP-2282753-A1 | ASSAY FOR PATHOGENIC CONFORMERS | Novartis AG (CH) | 2011-02-16 | — | — | EP | disclosed |
| US-7834144-B2 | Prion-specific peptoid reagents | NOVARTIS AG (CH) | 2010-11-16 | — | — | US | disclosed |
| WO-2009134942-A1 | ASSAY FOR PATHOGENIC CONFORMERS | NOVARTIS AG. (CH) | 2009-11-05 | — | — | WO | disclosed |
| EP-1931695-A1 | PRION-SPECIFIC PEPTOID REAGENTS | Novartis AG (CH) | 2008-06-18 | — | — | EP | disclosed |
| US-20070087972-A1 | Prion-specific peptoid reagents | NOVARTIS AG (CH) | 2007-04-19 | — | — | US | disclosed |
| WO-2007030804-A1 | PRION-SPECIFIC PEPTOID REAGENTS | NOVARTIS AG (CH) | 2007-03-15 | — | — | WO | disclosed |
| US-7026282-B1 | Peptide antagonists of the human urokinase receptor and method for selecting them | Cancerforskningsfonden AF 1989 (Fonden Til Fremme AF Exsperimentel Cancerforskning) (DK) | 2006-04-11 | — | — | US | disclosed |
| WO-2000001802-A2 | PEPTIDE ANTAGONISTS OF THE HUMAN UROKINASE RECEPTOR AND METHOD FOR SELECTING THEM | CANCERFORSKNINGSFONDEN AF 1989 (FONDEN TIL FREMME AF EKSPERIMENTEL CANCERFORSKNING) (DK) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070087972-A1 | Prion-specific peptoid reagents | PRNP, PARL, PCNP | KMT2A 4687/4885MEN1 2738/4885ATM 4712/4885 |
| US-20120027677-A1 | Prion-specific peptoid reagents | PRNP, PARL, PCNP | KMT2A 4687/4885MEN1 2738/4885ATM 4712/4885 |
| US-12281180-B2 | Peptoid-peptide macrocycles, pharmaceutical compositions and methods of using the same | WNT1, WNT3, WNT3A | KMT2A 4855/4885MEN1 1000/4885ATM 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.